Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash
How this was made
The 30-second read
Why it matters
Key trading takeaways are (1) multiple dated milestones (AMP-101 Phase 1; insulin aspart launch 2027; recombinant human insulin filing H1 next year; ipratropium generic launch in 2026), (2) branded-product sales/trajectory guidance (BAQSIMI peak sales and Primatene MIST growth), and (3) a stated capital runway (cash/EBITDA plus refinancing intent) to support Phase 2 development.
Market read
Provides a multi-catalyst roadmap and capital runway that can influence positioning in AMPH ahead of near- and medium-term clinical and commercial milestones.
What to watch
Refinancing/debt assumptions and the cost of later-stage oncology trials could become a future overhang if trial timelines or funding needs change.
Background
The piece is a company-led update describing Amphastar’s pivot toward proprietary drugs and biosimilars, alongside branded-product momentum and manufacturing capabilities.
Ticker impact
Amphastar outlined proprietary pipeline progress (AMP-101 Phase 1; AMP-107/109/110) and reiterated BAQSIMI/Primatene MIST growth forecasts and 2026 launch plans.
Moderately positive bias; traders may re-rate the stock on clearer development funding and multiple catalysts (AMP-101 Phase 1, insulin aspart 2027, ipratropium launch).
The article contains multiple specific, company-attributable forward-looking datapoints (launch timing, forecasts, cash/EBITDA/debt/refinancing intent) that can drive incremental positioning, though it is not a fresh regulatory/earnings print.
Market effects
Reinforces demand for inhalation/generic and biosimilar manufacturing scale, and highlights competitive pressure in generic GLP-1 markets.
Limited; primarily US specialty pharma execution and FDA-facing timelines.
Some overseas manufacturing footprint (China/France) and multi-country BAQSIMI distribution, but no new international regulatory event.
Counterpoint
Proprietary programs are still early (Phase 1/2), so the market may discount much of the upside until clinical readouts; generic GLP-1 is framed as crowded.
Key entities
- companyAmphastar Pharmaceuticals
Specialty pharma update covering proprietary pipeline, biosimilars, branded products, and funding runway.
- productBAQSIMI
Intranasal glucagon product; Amphastar forecasts peak annual sales and long-term incremental adjusted peak EPS.
- productPrimatene MIST
OTC asthma inhaler; Amphastar plans sampling/advertising and forecasts high-single-digit growth.
- pipeline_programAMP-101
Intranasal epinephrine for anaphylaxis in Phase 1 studies.
- pipeline_programAMP-107
Wet AMD program using an eye-drop approach (reducing injection reliance).
